Glioblastoma Multiforme Treatment (GBM)

Glioblastoma Multiforme Treatment (GBM)

Global Glioblastoma Multiforme Treatment (GBM) Market to Reach US$4.8 Billion by 2030

The global market for Glioblastoma Multiforme Treatment (GBM) estimated at US$2.9 Billion in the year 2023, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Surgery Treatment segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$781.5 Million While China is Forecast to Grow at 7.0% CAGR

The Glioblastoma Multiforme Treatment (GBM) market in the U.S. is estimated at US$781.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$741.3 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Global Glioblastoma Multiforme (GBM) Treatment Market - Key Trends & Drivers Summarized

Why Is Glioblastoma Multiforme Challenging to Treat?

Glioblastoma multiforme (GBM), one of the most aggressive and fatal forms of brain cancer, presents unique treatment challenges due to its rapid growth, complex cellular structure, and resistance to conventional therapies. GBM tumors are highly invasive, spreading quickly into surrounding brain tissues and making complete surgical removal difficult. This complex biology necessitates a multi-modal treatment approach, typically involving surgery, radiation, and chemotherapy. Even with these aggressive treatments, GBM is known for its high recurrence rate, which has led researchers and pharmaceutical companies to explore new, innovative therapies to improve survival rates and patient quality of life.

How Are Targeted Therapies and Immunotherapies Revolutionizing GBM Treatment?

Advancements in targeted therapies and immunotherapies are offering new hope for GBM treatment. Targeted therapies, such as tyrosine kinase inhibitors, specifically target cancer cells, potentially reducing damage to surrounding healthy brain tissues. Immunotherapies, including CAR-T cell therapy and oncolytic virus therapy, harness the body’s immune system to identify and attack cancer cells, showing promise in managing GBM’s aggressive behavior. These therapies are particularly valuable in recurrent GBM cases, where traditional therapies often fall short. While these treatments are still in various stages of research and clinical trials, they are helping to shape a more personalized approach to GBM treatment.

What Role Do Clinical Trials Play in Advancing GBM Therapies?

Clinical trials are crucial in developing effective GBM therapies, as they provide a structured pathway to test the safety and efficacy of novel treatments. Numerous clinical trials are underway to evaluate new drug combinations, immunotherapy protocols, and innovative delivery methods, such as intracranial drug delivery systems that bypass the blood-brain barrier. The FDA and other regulatory bodies are also granting special designations like “Orphan Drug” status to certain GBM drugs, fast-tracking their development. Patient advocacy groups and pharmaceutical partnerships are funding these clinical trials, supporting advancements in a field where few treatment options currently exist.

What Drives the Growth of the Glioblastoma Multiforme Treatment Market?

The growth in the GBM treatment market is driven by several factors, including the unmet need for effective therapies, advancements in targeted and immunotherapies, and robust clinical trial activity. The high recurrence rate and poor prognosis associated with GBM have intensified the search for new treatments, driving pharmaceutical investment and research. Breakthroughs in targeted and immune-based therapies offer promising alternatives to traditional treatments, while regulatory support for clinical trials is accelerating the introduction of novel treatments. Additionally, patient advocacy and pharmaceutical collaborations are sustaining this momentum, positioning the GBM treatment market for significant growth as it addresses a critical therapeutic gap.

SCOPE OF STUDY:

The report analyzes the Glioblastoma Multiforme Treatment (GBM) market in terms of US$ Million by the following End-Use; Treatment, and Geographic Regions/Countries:

Segments:
Treatment (Radiation Therapy, Surgery, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy); End-Use (Hospitals, Clinics, Ambulatory Surgery Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

• Amneal Pharmaceuticals, Inc.
• CARsgen Therapeutics
• Epitopoietic Research Corporation (ERC.SA.)
• F. Hoffmann-La Roche AG
• GBM Communications
• GBM Digital Technologies
• ImmunoCellular Therapeutics Ltd.
• Ivy Foundation
• Sapience Therapeutics
• SonALAsense

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.